Asklepios BioPharmaceutical, Inc. (AskBio)
78 articles about Asklepios BioPharmaceutical, Inc. (AskBio)
-
Read the latest overview of people coming and going from executive positions at biopharma companies covered by BioSpace.
-
Artificial intelligence and a flood of data in the pharmaceutical industry will likely change some of the current functions of its data scientists, experts say, but the ability to learn and adapt to new technologies will remain key in this role.
-
First Patient Randomized in AskBio Phase II Gene Therapy Trial for Congestive Heart Failure
2/16/2024
Bayer AG and Asklepios BioPharmaceutical, Inc. announced that the first patient has been randomized in GenePHIT, a Phase II trial of AB-1002 for the treatment of congestive heart failure.
-
AskBio Presents Preliminary Data from Phase 1 Trial of Gene Therapy for Congestive Heart Failure (CHF) at the 2023 American Heart Association Scientific Sessions
11/12/2023
Asklepios BioPharmaceutical, Inc., a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG, presented first-in-human data from a Phase 1 trial investigating AB-1002 for the treatment of patients with congestive heart failure at this year's American Heart Association Scientific Sessions, which are being held in Philadelphia, U.S., from November 11 to 13, 2023.3,4
-
AskBio Contribution to Advancing Gene Therapy Highlighted at ESGCT 30th Congress
10/23/2023
Asklepios BioPharmaceutical, Inc. today announced that 20 company abstracts will be presented at the European Society for Gene and Cell Therapy (ESGCT) 30th Congress, which is being held in Brussels, Belgium, from October 24 to 27, 2023.
-
AskBio Announces First Patient Dosed in Phase 1 / Phase 2 Trial of AB-1003 Gene Therapy for Limb-Girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9)
8/3/2023
Asklepios BioPharmaceutical, Inc. (AskBio), a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG, today announced that the first patient has been dosed in Phase 1 / Phase 2 LION-CS101 clinical trial of patients with limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9).
-
AskBio Announces 11 Presentations at the American Society of Gene and Cell Therapy 26th Annual Meeting in 2023
5/11/2023
Asklepios BioPharmaceutical, Inc., a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG, will deliver 11 presentations offering insights into the research and development of adeno-associated virus therapies for a range of diseases at the American Society of Gene and Cell Therapy 26th Annual Meeting taking place May 16–20, 2023, in Los Angeles, USA.
-
TAAV launches new corporate brand as a reflection of its transformation
5/2/2023
TAAV Biomanufacturing Solutions S.L.U. presents a new brand that supports the company's transformation and purpose, which is to be the DNA manufacturing partner of choice for developers of recombinant adeno-associate virus technologies and thus become a fundamental part of the gene therapy industry.
-
AskBio to Present Phase 1b Results Investigating AB-1005 (formerly AAV2-GDNF) as Treatment for Parkinson's Disease at AD/PDTM 2023 International Conference on Alzheimer's and Parkinson's Diseases
3/29/2023
Asklepios BioPharmaceutical, Inc. (AskBio) will present the preliminary results of a clinical Phase 1b study investigating the safety and efficacy of AB-1005, an adeno-associated virus 2 (AAV2) glial cell line-derived neurotrophic factor (GDNF) gene therapy for the treatment of mild to moderate Parkinson's disease at the AD/PD™ 2023 Advances in Science & Therapy Conference taking place March 28–April 1, 2023.
-
AskBio Announces Gustavo Pesquin as New CEO
3/9/2023
Asklepios BioPharmaceutical, Inc., a wholly owned and independently operated subsidiary of Bayer AG, announced that Gustavo Pesquin will become the company's next Chief Executive Officer as of March 11, 2023.
-
AskBio Receives European Commission Orphan Drug Designation through its EU-Based subsidiary BrainVectis for AB-1003, a Novel Investigational AAV Gene Therapy for the Treatment of Limb-Girdle Muscular Dystrophy (LGMD)
2/27/2023
Asklepios BioPharmaceutical, Inc. (AskBio), a wholly owned and independently operated subsidiary of Bayer AG, announced today that the European Commission (EC) has granted orphan drug designation for AB-1003 (also known as LION-101)* for the treatment of limb-girdle muscular dystrophy (LGMD).
-
Viralgen receives cGMP certification to produce rAAV commercial grade product at new facility in San Sebastian, Spain
1/9/2023
Viralgen Vector Core, an independently operated subsidiary of Asklepios BioPharmaceutical, Inc., and a member of the Bayer worldwide group of companies, has received Certified Good Manufacturing Practices certification for the manufacture of human medicinal products, investigational medicinal products and sterile or biological active substances.
-
ReCode Therapeutics Announces Strategic Collaboration with AskBio to Explore Single Vector Gene-Editing Platform
1/9/2023
ReCode Therapeutics announced today it has signed a multi-year research collaboration and option agreement with Asklepios BioPharmaceutical, Inc. (AskBio).
-
AskBio Announces Strategic Collaboration with ReCode Therapeutics to Explore Single Vector Gene Editing Platform
1/9/2023
Asklepios BioPharmaceutical, Inc. announced today that it has signed a multi-year research collaboration and option agreement with ReCode Therapeutics.
-
Viralgen GMP certification rAAV commercial product
1/9/2023
Viralgen Vector Core, an independently operated subsidiary of Asklepios BioPharmaceutical, Inc., and a member of the Bayer worldwide group of companies, has received Certified Good Manufacturing Practices certification for the manufacture of human medicinal products, investigational medicinal products and sterile or biological active substances.
-
Recombinant Adeno-Associated Virus (rAAV) Technology Pioneered by AskBio's Dr. Jude Samulski is Key Component of All FDA Approved AAV Gene Therapeutics
12/20/2022
Asklepios BioPharmaceutical, Inc. (AskBio) today announced that the FDA's approval of a new adeno-associated virus (AAV) gene therapy to treat adults with hemophilia B marks another milestone for the advancement of AAV therapeutics and highlights the important research contributions made by AskBio Co-Founder, President and Chief Scientific Officer, R. Jude Samulski, PhD.
-
AskBio Co-Founder Jude Samulski Receives Inaugural European Society of Gene and Cell Therapy Founders Award
10/28/2022
Asklepios BioPharmaceutical, Inc. announced that R. Jude Samulski, Ph.D., AskBio President, Co-Founder and Chief Scientific Officer, received the inaugural European Society of Gene and Cell Therapy Founders Award in Edinburgh, Scotland, during the recent ESGCT 29th Congress.
-
BrainVectis will begin assessing a gene therapy for Huntington’s disease in France after receiving clearance from health authorities there to conduct a Phase I/II study.
-
BrainVectis, a subsidiary of AskBio, receives clearance to conduct Phase I/II clinical trial in France for its novel gene therapy for early-stage Huntington's Disease
8/23/2022
Asklepios BioPharmaceutical, Inc., a wholly owned and independently operated subsidiary of Bayer AG, has received clearance to conduct a Phase I/II trial for its novel Huntington's Disease gene therapy, BV-101, in France through its subsidiary BrainVectis.
-
AskBio Bolsters its Global Leadership Team with Two New Executives
8/11/2022
Asklepios BioPharmaceutical , Inc. is adding two industry veterans to advance clinical operations and lead corporate communications.